Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

Inclusion Criteria: * Subject who the investigator believes that their parent(s)/Legally Authorized Representative(s) (LARs) can and will comply with the requirements of the protocol. * A male or female American Indian infant between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination. * Voluntary, written informed consent obtained from the parents/LAR(s) of the subject. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by a witness. * Healthy subject as established by medical history and clinical examination before entering into the study. * Born after a gestation period of more than 35 6/7 weeks. Exclusion Criteria: For all infants: * Child in care. * Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Chronic administration of immunosuppressants or other immune-modifying drugs since birth. * Planned administration/administration of a vaccine not foreseen by the study protocol starting from 30 days before each dose and ending 30 days after each dose of study vaccines, with the exception of licensed inactivated influenza vaccines and recommended pediatric vaccines. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * Previous vaccina…